Australian Clinical Labs Limited (ASX:ACL)

Market Cap	416.02M -42.9%
Revenue (ttm)	737.49M +1.3%
Net Income	26.31M -14.2%
EPS	0.14 -8.2%
Shares Out	189.96M
PE Ratio	15.54
Forward PE	12.54
Dividend	0.13 (5.76%)
Ex-Dividend Date	Mar 12, 2026

Volume	168,985
Average Volume	1,070,696
Open	2.200
Previous Close	2.190
Day's Range	2.170 - 2.220
52-Week Range	2.080 - 3.740
Beta	1.01
RSI	32.67
Earnings Date	Feb 16, 2026

About Australian Clinical Labs

Australian Clinical Labs Limited provides pathology diagnostic services in Australia. The company offers range of services, including molecular cancer, harmony NIPT, genetic carrier screening and other antenatal, cardiac, and commercial drug and alcohol testing services; chemical pathology, haematology, histopathology and cytopathology, serology and microbiology, allergy and immunology, and veterinary and functional pathology services; pathology services for clinical trials; and CPD programs. It serves doctors, patients, and corporate clients. ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2020
• Employees: 4,700
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ACL

Financial Performance

In fiscal year 2025, Australian Clinical Labs's revenue was 741.27 million, an increase of 6.45% compared to the previous year's 696.37 million. Earnings were 32.43 million, an increase of 35.50%.